Avadel Pharma (AVDL) Tops Q2 EPS by 4c

Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $37.47 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Trump: everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure "nuclear honesty" long into future
• Texas AG Paxton announces ongoing investigation into Carnival over data breach